The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum
Open accessAbstract
Two specific reversal agents for direct oral anticoagulants (DOACs) have been approved in the United States: idarucizumab for dabigatran reversal and andexanet alfa for apixaban and rivaroxaban reversal. Non‐specific prohemostatic agents such as prothrombin complex concentrate (PCC) and activated PCC have also been used for DOAC reversal. The goal of this document is to provide comprehensive guidance from the Anticoagulation Forum, a North American organization of anticoagulation providers, regarding use of DOAC reversal agents. We discuss indications for reversal, provide guidance on how the individual reversal agents should be administered, and offer suggestions for stewardship at the health system level.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., Camm, A. J., Weitz, J. I., Lewis, B. S., Parkhomenko, A., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62343-0 · Cited by 5,051
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
Pollack, C. V., Reilly, P. A., van Ryn, J., Eikelboom, J. W., Glund, S., Bernstein, R. A., Dubiel, R., Huisman, M. V., Hylek, E. M., Kam, C.-W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707278 · Cited by 1,154
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
Connolly, S. J., Crowther, M., Eikelboom, J. W., Gibson, C. M., Curnutte, J. T., Lawrence, J. H., Yue, P., Bronson, M. D., Lu, G., Conley, P. B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814051 · Cited by 960
Self-citationUS Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014
Shehab, N., Lovegrove, M. C., Geller, A. I., Rose, K. O., Weidle, N. J., & Budnitz, D. S. (2016) · JAMA · doi:10.1001/jama.2016.16201 · Cited by 655
National trends in ambulatory oral anticoagulant use
Barnes, G. D., Lucas, E., Alexander, G. C., & Goldberger, Z. D. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.05.044 · Cited by 598
Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants
Cuker, A., Siegal, D. M., Crowther, M. A., & Garcia, D. A. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.05.065 · Cited by 449
Self-citationDoherty, J. U., Gluckman, T. J., Hucker, W. J., Januzzi, J. L., Ortel, T. L., Saxonhouse, S. J., & Spinler, S. A. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.024 · Cited by 441
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation
Calkins, H., Willems, S., Gerstenfeld, E. P., Verma, A., Schilling, R., Hohnloser, S. H., Okumura, K., Serota, H., Nordaby, M., Guiver, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701005 · Cited by 430
Cappato, R., Marchlinski, F. E., Hohnloser, S. H., Naccarelli, G. V., Xiang, J., Wilber, D. J., Ma, C.-S., Hess, S., Wells, D. S., Juang, G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv177 · Cited by 422
Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants
Samuelson, B. T., Cuker, A., Siegal, D. M., Crowther, M., & Garcia, D. A. (2017) · Chest · doi:10.1016/j.chest.2016.08.1462 · Cited by 345
Self-citationTomaselli, G. F., Mahaffey, K. W., Cuker, A., Dobesh, P. P., Doherty, J. U., Eikelboom, J. W., Florido, R., Hucker, W., Mehran, R., Messé, S. R., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.1085 · Cited by 345
Self-citationChai-Adisaksopha, C., Crowther, M., Isayama, T., & Lim, W. (2014) · Blood · doi:10.1182/blood-2014-07-590323 · Cited by 326
Self-citationMajeed, A., Ågren, A., Holmström, M., Bruzelius, M., Chaireti, R., Odeberg, J., Hempel, E.-L., Magnusson, M., Frisk, T., & Schulman, S. (2017) · Blood · doi:10.1182/blood-2017-05-782060 · Cited by 326
Kubitza, D., Becka, M., Roth, A., & Mueck, W. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802361499 · Cited by 268
Gross, P., Ritchie, B., Nahirniak, S., Lin, Y., Lieberman, L., Carrier, M., Crowther, M., Ghosh, I., Lazo-Langner, A., Zondag, M., et al. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1636541 · Cited by 218
Self-citationSpyropoulos, A. C., Al‐Badri, A., Sherwood, M. W., & Douketis, J. D. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13305 · Cited by 208
Formella, S., Wiegert, E., Moschetti, V., Slowinski, T., Neumayer, H.-H., Liesenfeld, K.-H., Lehr, T., Härtter, S., Friedman, J., Khadzhynov, D., et al. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-08-0573 · Cited by 207
Birnie, D. H., Healey, J. S., Wells, G. A., Ayala-Paredes, F., Coutu, B., Sumner, G. L., Becker, G., Verma, A., Philippon, F., Kalfon, E., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy413 · Cited by 192
Chai‐Adisaksopha, C., Hillis, C., Isayama, T., Lim, W., Iorio, A., & Crowther, M. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13139 · Cited by 190
Self-citationIdarucizumab: The Antidote for Reversal of Dabigatran
Eikelboom, J. W., Quinlan, D. J., van Ryn, J., & Weitz, J. I. (2015) · Circulation · doi:10.1161/circulationaha.115.019628 · Cited by 164
Reversal agents for non-vitamin K antagonist oral anticoagulants
Levy, J. H., Douketis, J. D., & Weitz, J. I. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.223 · Cited by 141
Douketis, J. D., Spyropoulos, A. C., Anderson, J., Arnold, D. M., Bates, S. M., Blostein, M. D., Carrier, M., Caprini, J. A., Clark, N. P., Coppens, M., et al. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-08-0553 · Cited by 99
Kjerpeseth, L. J., Ellekjær, H., Selmer, R. M., Ariansen, I., Furu, K., & Skovlund, E. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2296-1 · Cited by 96
Crowther, M. A., Levy, G. G., Lu, G., Leeds, J. M., Lin, J. P., Pratikhya, P., Conley, P. B., Connolly, S. J., & Curnutte, J. T. (2014) · Blood · doi:10.1182/blood.v124.21.4269.4269 · Cited by 93
Self-citationDOACs – advances and limitations in real world
Lee, L. H. (2016) · Thrombosis Journal · doi:10.1186/s12959-016-0111-3 · Cited by 93
Direct Oral Anticoagulant- or Warfarin-Related Major Bleeding
Xu, Y., Schulman, S., Dowlatshahi, D. D., Holbrook, A. M., Simpson, C. S., Shepherd, L. E., Wells, P. S., Giulivi, A., Gomes, T., Mamdani, M., et al. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.02.009 · Cited by 91
Risk of Intracranial Hemorrhage in Ground‐level Fall With Antiplatelet or Anticoagulant Agents
Ganetsky, M., Lopez, G. J., Coreanu, T., Novack, V., Horng, S., Shapiro, N. I., & Bauer, K. A. (2017) · Academic Emergency Medicine · doi:10.1111/acem.13217 · Cited by 75
Chai‐Adisaksopha, C., Hillis, C., Lim, W., Boonyawat, K., Moffat, K. A., & Crowther, M. A. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13117 · Cited by 70
Self-citationReversing factor Xa inhibitors – clinical utility of andexanet alfa
Kaatz, S., Bhansali, H. M., Gibbs, J., Lavender, R. C., Mahan, C. E., & Paje, D. G. (2017) · Journal of Blood Medicine · doi:10.2147/jbm.s121550 · Cited by 55
Self-citationSchulman, S., Ritchie, B. C., Nahirniak, S., Gross, P. L., Carrier, M., Majeed, A., Hwang, H.-G., & Zondag, M. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.02.010 · Cited by 54
Pharmacological reversal of the direct oral anticoagulants—A comprehensive review of the literature
Shaw, J. R., & Siegal, D. M. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12089 · Cited by 46
Spiller, H. A., Mowry, J. B., Aleguas, A., et al. (2015) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2015.07.014 · Cited by 37
Idarucizumab for dabigatran overdose
Peetermans, M., Pollack, C. V., Reilly, P. A., Liesenborghs, L., Jacquemin, M. G., Levy, J. H., Weitz, J. I., & Verhamme, P. B. (2016) · Clinical Toxicology · doi:10.1080/15563650.2016.1187737 · Cited by 36
The scope and value of an anticoagulation stewardship program at a community teaching hospital
Wychowski, M. K., Ruscio, C. I., Kouides, P. A., & Sham, R. L. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1455-z · Cited by 34
Lu, G., Pine, P. R., Leeds, J. M., DeGuzman, F. R., Pratikhya, P., Lin, J. P., Malinowski, J., Hollenbach, S. J., Curnutte, J. T., & Conley, P. B. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195122 · Cited by 33
Massive human rivaroxaban overdose
Lehmann, T., Hofer, K. E., Baumann, M., Hasler, K., Ceschi, A., Kupferschmidt, H., Rohde, G., & Korte, W. C. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-02-0138 · Cited by 27
Anti-Xa activity in apixaban overdose: a case report
Barton, J., Wong, A., & Graudins, A. (2016) · Clinical Toxicology · doi:10.1080/15563650.2016.1204453 · Cited by 21
Specific antidotes for bleeding associated with direct oral anticoagulants
Burnett, A., Siegal, D. M., & Crowther, M. A. (2017) · BMJ · doi:10.1136/bmj.j2216 · Cited by 20
Self-citationLevine, M., Beuhler, M. C., Pizon, A. F., Cantrel, F. L., Spyres, M. B., LoVecchio, F., Skolnik, A. B., & Brooks, D. E. (2017) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2017.08.046 · Cited by 20
Repplinger, D., Hoffman, R. S., Nelson, L. S., Hines, E. Q., Howland, M., & Su, M. K. (2016) · Clinical Toxicology · doi:10.1080/15563650.2016.1187736 · Cited by 18
The X factor: Lack of bleeding after an acute apixaban overdose
Leikin, S. M., Patel, H., Welker, K. L., & Leikin, J. B. (2016) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2016.11.035 · Cited by 17
Evaluation of anticoagulation selection for acute venous thromboembolism
Badreldin, H. A., Nichols, H., Rimsans, J., & Carter, D. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1417-5 · Cited by 16
Reversal of Betrixaban-Induced Anticoagulation in Healthy Volunteers By Andexanet Alfa
Crowther, M. A., Lu, G., Leeds, J. M., Lin, J. P., Conley, P. B., Gold, A., Connolly, S. J., & Curnutte, J. T. (2016) · Blood · doi:10.1182/blood.v128.22.143.143 · Cited by 16
Self-citationDabigatran deliberate overdose: two cases and suggestions for laboratory monitoring
Vlad, I. A., Armstrong, J., Ridgley, J., & Pascu, O. (2016) · Clinical Toxicology · doi:10.3109/15563650.2015.1126287 · Cited by 10
Cited by
European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke
Berge, E., Whiteley, W., Audebert, H., De Marchis, G., Fonseca, A. C., Padiglioni, C., Pérez de la Ossa, N., Strbian, D., Tsivgoulis, G., & Turc, G. (2021) · European Stroke Journal · doi:10.1177/2396987321989865 · Cited by 1,355
Tomaselli, G. F., Mahaffey, K. W., Cuker, A., Dobesh, P. P., Doherty, J. U., Eikelboom, J. W., Florido, R., Gluckman, T. J., Hucker, W. J., Mehran, R., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.04.053 · Cited by 397
Self-citationPuy, L., Parry-Jones, A. R., Sandset, E. C., Dowlatshahi, D., Ziai, W., & Cordonnier, C. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00424-7 · Cited by 323
Kumbhani, D. J., Cannon, C. P., Beavers, C. J., Bhatt, D. L., Cuker, A., Gluckman, T. J., Marine, J. E., Mehran, R., Messe, S. R., Patel, N. S., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.09.011 · Cited by 308
Self-citation
Metadata
- Authors
- Cuker, A., Burnett, A., Triller, D., Crowther, M., Ansell, J., Van Cott, E. M., Wirth, D., & Kaatz, S.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2019-04-16
- Volume
- 94
- Issue
- 6
- Pages
- 697-709
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W2934397726
- Cited by
- 315
- References
- 44
- FWCI
- 29.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.